Drug Type CIK therapy |
Synonyms- |
Target |
Mechanism CD16a modulators(Low affinity immunoglobulin gamma Fc region receptor III-A modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseIND Approval |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | IND Approval | TW | 31 May 2023 | |
Colorectal Cancer | IND Approval | TW | 31 May 2023 | |
Glioblastoma Multiforme | IND Approval | TW | 31 May 2023 | |
Liver Cancer | IND Approval | TW | 31 May 2023 | |
Lung Cancer | IND Approval | TW | 31 May 2023 | |
Ovarian Epithelial Carcinoma | IND Approval | TW | 31 May 2023 | |
Pancreatic Cancer | IND Approval | TW | 31 May 2023 |